Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 50, Issue 1 (Jan 2012)

Issues

The human epidermal growth factor receptor 2 (HER2)

Laura J. Tafe
  • Department of Pathology, Dartmouth Medical School, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH, USA
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Gregory J. Tsongalis
  • Department of Pathology, Dartmouth Medical School, Dartmouth Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2011-09-15 | DOI: https://doi.org/10.1515/cclm.2011.707

Abstract

The declared “war on cancer” aimed to eradicate this disease using our knowledge of cancer cell biology to develop novel therapeutics. One such target of these novel therapies has been the human epidermal growth factor receptor 2 (HER2) gene. Unique in the approach to abolishing function of this gene coded receptor, it was the first target of new monoclonal antibody therapy targeting the extracellular receptor and now also a target of small molecule drugs against the intracellular tyrosine kinase domain. In this instance, it was also one of the first applications of personalized medicine requiring companion diagnostics. In this manuscript, we review the biology and clinical applications of HER2 as a biomarker of disease and as a therapeutic target.

Keywords: breast cancer; gastric cancer; Her2; lapatinib; trastuzumab

About the article

Corresponding author: Laura J. Tafe, MD, Department of Pathology, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA Phone: +1-603-650-7211, Fax: 1-603-650-7214


Received: 2011-06-08

Accepted: 2011-08-12

Published Online: 2011-09-15

Published in Print: 2012-01-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm.2011.707.

Export Citation

©2011 by Walter de Gruyter Berlin Boston. Copyright Clearance Center

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Raquel C.B. Marques, Estefanía Costa-Rama, Subramanian Viswanathan, Henri P.A. Nouws, Agustín Costa-García, Cristina Delerue-Matos, and M. Begoña González-García
Sensors and Actuators B: Chemical, 2017
[2]
Raquel C.B. Marques, Subramanian Viswanathan, Henri P.A. Nouws, Cristina Delerue-Matos, and M. Begoña González-García
Talanta, 2014, Volume 129, Page 594
[3]
Peppino Mirabelli and Mariarosaria Incoronato
BioMed Research International, 2013, Volume 2013, Page 1
[4]
Ashley G. Rivenbark, Siobhan M. O’Connor, and William B. Coleman
The American Journal of Pathology, 2013, Volume 183, Number 4, Page 1113
[5]
Jolieke G. van Oosterwijk, Jakob K. Anninga, Hans Gelderblom, Anne-Marie Cleton-Jansen, and Judith V.M.G. Bovée
Hematology/Oncology Clinics of North America, 2013, Volume 27, Number 5, Page 1021

Comments (0)

Please log in or register to comment.
Log in